2025
Modeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study.
Ghali F, Rahman S, James S. Modeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study. Journal Of Clinical Oncology 2025, 43: 517-517. DOI: 10.1200/jco.2025.43.5_suppl.517.Peer-Reviewed Original ResearchStandard of careKEYNOTE-564KEYNOTE-426Renal cell carcinomaCheckpoint inhibitorsUnadjusted hazard ratioOverall survivalControl armHazard ratioPatient-level survival dataFirst-line settingImproved overall survivalProportion of patientsKaplan-Meier plotsMortality riskSurvival parametersControl group patientsOne-year mortality riskCell carcinomaFirst-lineSurvival outcomesControl patientsGroup patientsSurvival curvesArm treatmentUltrasound for midgut volvulus and malrotation: frequency and predictors of a non-diagnostic examination in a multi-institutional cohort
El-Ali A, Schiess D, Van Tassel D, Le Cacheux C, Lala S, Riemann M, Tutman J, Sher A, Sammer M, Navarro O, Nguyen H, Silva C. Ultrasound for midgut volvulus and malrotation: frequency and predictors of a non-diagnostic examination in a multi-institutional cohort. Pediatric Radiology 2025, 1-11. PMID: 39903261, DOI: 10.1007/s00247-024-06141-x.Peer-Reviewed Original ResearchNon-diagnostic USBowel gas patternNon-diagnostic examinationsProportion of examinationsNon-diagnosticMidgut volvulusBlinded reviewersRetrospective multi-institutional studyDiagnosis of midgut volvulusFirst-line imaging modalityMulti-institutional cohortClinical follow-upUpper GI seriesStepwise logistic regressionMulti-institutional sampleGas patternFirst-lineUltrasound reportsBlinded interpretationStudy of childrenFollow-upGI seriesMalrotationResultsIn totalDiagnostic examsAficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Garcia-Pavia P, Bilen O, Burroughs M, Costabel J, de Barros Correia E, Dybro A, Elliott P, Lakdawala N, Mann A, Nair A, Nassif M, Poulsen S, Reant P, Schulze P, Wang A, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Meng L, Sohn R, Wohltman A, Fifer M, Investigators M. Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Failure 2025, 13: 346-357. PMID: 39909646, DOI: 10.1016/j.jchf.2024.11.011.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyStandard-of-careCardiac myosin inhibitorStandard-of-care medicationsBaseline characteristicsSymptomatic obstructive hypertrophic cardiomyopathyNondihydropyridine calcium channel blockersBaseline characteristics of patientsStandard-of-care drugsSecond-line therapyFirst-line therapyCalcium channel blockersCharacteristics of patientsImprove exercise capacityMyosin inhibitorFirst-lineBeta-blockersHypertrophic cardiomyopathyExercise capacityAlleviate symptomsPatientsAficamtenMedicationTherapyStudy designNivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.
Janjigian Y, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Elimova E, Bruges R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, McCraith S, Hu N, Zhang J, Shitara K. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649. Journal Of Clinical Oncology 2025, 43: 398-398. DOI: 10.1200/jco.2025.43.4_suppl.398.Peer-Reviewed Original ResearchProgression-free survivalBlinded independent central reviewObjective response rateCombined positive scorePD-L1Overall survivalFollow-upCheckMate 649OS ratesPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Anti-PD-1Death-ligand 1Duration of responseIndependent central reviewMinimum follow-upFollow-up resultsLong-term survivalOS benefitCentral reviewCombination therapyFirst-linePrimary endpointNivolumabFirst-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
Shen L, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Hu N, McCraith S, Liu T. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. Journal Of Clinical Oncology 2025, 43: 392-392. DOI: 10.1200/jco.2025.43.4_suppl.392.Peer-Reviewed Original ResearchBlinded independent central reviewObjective response rateProgression-free survivalCombined positive scorePD-L1CheckMate 649Overall survivalFollow-upSurvival benefitPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Long-term survival benefitStudy populationDual primary endpointsDeath-ligand 1Gastroesophageal junction cancerDuration of responseAdvanced gastric cancerIndependent central reviewOS ratesJunction cancerCentral reviewPrimary endpointFirst-lineShort- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature
Taki Y, Kono T, Matsuda T, Kozu R, Fujimoto M, Sakuma I, Hashimoto N, Horiguchi K, Higuchi Y, Tanaka T. Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature. Endocrine Journal 2025, ej24-0548. PMID: 39842795, DOI: 10.1507/endocrj.ej24-0548.Peer-Reviewed Original ResearchSomatostatin receptor 5GLP-1RAsContinuous glucose monitoringGrowth hormoneOptimal first-line treatmentGLP-1 receptor agonistsEfficacy of GLP-1RAsMultireceptor somatostatin analogsEffects of pasireotideFirst-line therapyFirst-line treatmentInsulin-like growth factor-1Optimal treatment strategyControlling hormone levelsEarly detectionGrowth factor-1Pasireotide therapyInhibit insulin secretionSomatostatin analogsFirst-lineReceptor agonistsTreatment optionsPasireotideReceptor 5Treatment strategies
2024
Diastolic dysfunction evaluation by cardiovascular magnetic resonance derived E, a, e’: Comparison to echocardiography
Lamy J, Xiang J, Shah N, Kwan J, Kim Y, Upadhyaya K, Reinhardt S, Meadows J, McNamara R, Baldassarre L, Peters D. Diastolic dysfunction evaluation by cardiovascular magnetic resonance derived E, a, e’: Comparison to echocardiography. Physiological Reports 2024, 12: e70078. PMID: 39604208, PMCID: PMC11602526, DOI: 10.14814/phy2.70078.Peer-Reviewed Original ResearchConceptsCardiovascular magnetic resonanceTransthoracic echocardiographyDiastolic dysfunctionDiastolic functionDiagnostic accuracy of cardiovascular magnetic resonanceEvaluate diastolic dysfunctionCardiovascular magnetic resonance imagingLeft atrial volumeMitral annular velocityHealthy age-matched subjectsComparison to echocardiographyMitral inflow velocityEvaluate diastolic functionAge-matched subjectsPresence of DDAtrial volumeDD gradeFirst-lineAnnular velocityDiagnostic accuracyImaging modalitiesMagnetic resonanceEchocardiographyALLTransthoracicQuo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024
Engel B, Assis D, Bhat M, Clusmann J, Joostrenth, Gerussi A, Londoño M, Oo Y, Schregel I, Sebode M, Taubert R, collaborators T, Diseases T. Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024. JHEP Reports 2024, 7: 101265. PMID: 39897612, PMCID: PMC11783120, DOI: 10.1016/j.jhepr.2024.101265.Peer-Reviewed Original ResearchAutoimmune hepatitisInternational AIH GroupLiver transplant-free survivalAlternative first-lineCAR-T cellsRare chronic liver diseaseTransplant-free survivalDrug-induced autoimmunityChronic autoimmune responseEuropean Reference NetworkImmune-mediated diseasesChronic liver diseaseInitiative clinical trialsInflammatory bowel diseaseDecreased quality of lifeAIH patientsSalvage therapyRemission rateFirst-lineAIH groupT cellsStandard treatmentAutoimmune responseB cellsExpert centersCost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding
Wang D, Wang D, Glaeser-Khan S, Moshashaian Asl R, Chetlapalli K, Ito S, Cuker A, Goshua G. Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding. Blood 2024, 144: 281-281. DOI: 10.1182/blood-2024-198803.Peer-Reviewed Original ResearchSevere iron deficiency anemiaHeavy menstrual bleedingIron deficiency anemiaOral ferrous sulfateIncremental cost-effectiveness ratioIV iron sucroseIV iron dextranFirst-line treatmentFirst-lineIron sucroseQuality-adjusted life expectancyOral ironSecond-lineDeterministic sensitivity analysisProbabilistic sensitivity analysesIron dextranMenstrual bleedingDeficiency anemiaIron deficiencyUS health system perspectiveTreated with oral ironIV iron supplementationIV iron treatmentOral iron therapyDevelopment of iron deficiencyDocetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo P, Zarif T, McClure H, Davidsohn M, Eid M, Spinelli G, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre R, Fornarini G, Pignata S, Procopio G, Santini D, Ravi P, Sweeney C, Heng D, De Giorgi U, Fizazi K, Russo A, Francini E, Group S. Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study. Clinical Genitourinary Cancer 2024, 22: 102230. PMID: 39461026, DOI: 10.1016/j.clgc.2024.102230.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAndrogen receptor signaling inhibitorsCastration-resistant prostate cancerAbiraterone acetateOverall survivalProstate cancerElderly patientsSignaling inhibitorsCohort of consecutive patientsSecond-line therapyStandard first-lineReal-world studySecond-lineConsecutive patientsTreatment toxicityFirst-lineD. CONCLUSIONSPatient comorbiditiesIdentified patientsRetrospective designToxicity outcomesD groupInternational cohortPatientsNo differenceReal‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series
Youkhana K, Batsuli G, Acharya S, Khan O, Tran D, Dvorak A, Recht M, Young G, Sidonio R, Abajas Y. Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series. Haemophilia 2024, 30: 1321-1331. PMID: 39297369, PMCID: PMC11659498, DOI: 10.1111/hae.15094.Peer-Reviewed Original ResearchConceptsEptacog betaFirst-line therapyBleeding eventsEptacog alfaCase seriesHemophilia APerioperative bleedingManagement of perioperative bleedingManagement of bleeding eventsMulti-institutional case seriesTraumatic bleeding eventsTreated bleeding eventsProthrombin complex concentrateRecombinant factor VIIaB (HBRetrospective case seriesMinor surgical proceduresHaemophilia treatment centresEffective bleeding controlFactor replacementFirst-lineHemophilia patientsAdverse eventsBleeding controlBleeding treatmentReal World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e96-e102. PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3LymphomaTuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.
Leveille E, Kothari S, Cosgun K, Mlynarczyk C, Müschen M. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. Cancer Discovery 2024, 14: 1577-1580. PMID: 39228298, DOI: 10.1158/2159-8290.cd-24-0644.Commentaries, Editorials and LettersCLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To T, Li S, Huntington S. CLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s345. DOI: 10.1016/s2152-2650(24)01263-1.Peer-Reviewed Original ResearchPer-patient per-monthPer-patient per-month costsChronic lymphocytic leukemiaBruton tyrosine kinase inhibitorFirst-line treatmentTyrosine kinase inhibitorsLymphocytic leukemiaMonths 0Kinase inhibitorsHealthcare costsCLL/small lymphocytic lymphomaFixed-duration treatmentFirst-line therapyOff-treatment periodMonths post-indexMonths pre-indexRetrospective observational studyClinical trial enrollmentUS health planCommercially insured patientsLymphocytic lymphomaPrimary cancerFirst-linePost-indexIbrutinibALL-438 Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy
Ashaye A, Chalandon Y, Boissel N, Fazioli K, Wang B, Aldoss I, Huang F, Leonard J, Szabo N, McCloskey C, Nair S, Dalal M, Hennessy M, Yeh T, Martinelli G, Badar T, Kantarjian H, Ribera J, Jabbour E. ALL-438 Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s270-s271. DOI: 10.1016/s2152-2650(24)01111-x.Peer-Reviewed Original ResearchMinimal residual diseasePh+ acute lymphoblastic leukemiaAcute lymphoblastic leukemiaMRD-negative CRFirst-line therapyLong-term EFSIndividual patient dataComplete remissionFirst-lineMRD analysisLymphoblastic leukemiaPrognostic indicatorAdult patientsPrognostic indicators of long-term survivalDiagnosed Ph+ ALLPhiladelphia chromosome-positive acute lymphoblastic leukemiaMinimal residual disease levelsMinimal residual disease statusMRD-negative complete remissionIndicators of long-term survivalIndividual patient data analysisAchievement of CRStudy-level meta-analysisKaplan-Meier methodLog-rank testMinimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy
Ashaye A, Chalandon Y, Boissel N, Fazioli K, Wang B, Aldoss I, Huang F, Leonard J, Szabo N, McCloskey C, Nair S, Dalal M, Hennessy M, Yeh T, Martinelli G, Badar T, Kantarjian H, Ribera J, Jabbour E. Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s161. DOI: 10.1016/s2152-2650(24)00430-0.Peer-Reviewed Original Research1968P Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)
Rosenberg J, Petrylak D, Flaig T, Hoimes C, Gupta S, O'Donnell P, Mar N, Friedlander T, Tagawa S, Bilen M, Brown J, McKay R, Merchan J, Srinivas S, Shetty A, Moreno B, Davis G, Wirtz H, Zhu Y, Milowsky M. 1968P Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC). Annals Of Oncology 2024, 35: s1139-s1140. DOI: 10.1016/j.annonc.2024.08.2053.Peer-Reviewed Original ResearchDevimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study
Philip P, Sahai V, Bahary N, Mahipal A, Kasi A, Lima C, Alistar A, Oberstein P, Golan T, Metges J, Lacy J, Fountzilas C, Lopez C, Ducreux M, Hammel P, Salem M, Bajor D, Benson A, Luther S, Pardee T, Van Cutsem E. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. Journal Of Clinical Oncology 2024, 42: 3692-3701. PMID: 39088774, DOI: 10.1200/jco.23.02659.Peer-Reviewed Original ResearchMetastatic pancreatic adenocarcinomaOverall survivalCPI-613Randomized phase III trialTreatment-emergent adverse eventsExperimental armDifficult-to-treat diseaseFavorable performance statusProgression-free survivalTreatment naive patientsFirst-line therapyPhase I studyPhase III trialsMedian OSMetastatic adenocarcinomaIII trialsFirst-linePerformance statusPancreatic adenocarcinomaAdverse eventsDevimistatDay 1Disease progressionControl armPatientsAssessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis
Yin X, Li Y, Rönn M, Li S, Yuan Y, Gift T, Hsu K, Salomon J, Grad Y, Yaesoubi R. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine 2024, 21: e1004424. PMID: 38976754, PMCID: PMC11262662, DOI: 10.1371/journal.pmed.1004424.Peer-Reviewed Original ResearchDrug susceptibility testingQuality-adjusted life yearsFirst-line therapyFirst-line antibioticsNet health benefitFirst-lineRetreatment regimensResistance prevalenceRapid drug susceptibility testingRate of treatment failureTreatment of gonorrheaIncidence of gonorrheaAssociated with gonorrheaEmpirical therapyTreatment failureEmpirical treatmentGonococcal infectionSusceptibility testingGonorrhea casesMSM populationGonorrheaCost-effectiveness analysisDiagnostic testsResistant strainsTherapyClinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Shah S, Clarke L, Davis M, Topal J, Shields R. Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal Of Antimicrobial Chemotherapy 2024, 79: 2017-2021. PMID: 38958234, DOI: 10.1093/jac/dkae205.Peer-Reviewed Original ResearchPseudomonas endocarditisFirst-lineClinical outcomesShorter time to treatment initiationFactors associated with treatment failureInvestigate clinical outcomes of patientsClinical outcomes of patientsTime to treatment initiationRate of adverse effectsProsthetic valve endocarditisFirst-line therapyOrgan transplant recipientsOutcomes of patientsInvestigate clinical outcomesIntracardiac complicationsDuke criteriaMicrobiological failureDrug discontinuationValve endocarditisCombination therapyTreatment failureTransplant recipientsDay mortalityInitial treatmentClinical benefit
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply